ClinicalTrials.gg
Active, not recruitingNCT06573866EQuALUpdated Aug 14, 2026

Enhancement of Quality of Work And Life

An interventional study of Preventive Participatory workplace intervention in Parkinson Disease, Hereditary Spastic Paraparesis and Cerebellar Ataxia, sponsored by Radboud University Medical Center. Active, not recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Radboud University Medical Center · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Parkinson Disease by Radboud University Medical Center — 6 open to participants now, 12 under way, 1 of them phase 3. Parkinson Disease · Radboud University Medical Center.

Enrollment
14th of 22
124 · median 188
Started
2024
with 2 others
No phase
15 of 34
3 open now
Primary completion
2027-03
later than 7 of 11 live
Registered
31st of 34
by date

Among the 34 studies in Parkinson Disease by Radboud University Medical Center, this one is the 14th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2024, is one of 15 with no phase, reaches primary completion later than 7 of the 11 other live ones, and was the 31st registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

6 of the 34 studies in Parkinson Disease by Radboud University Medical Center are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Parkinson Disease by Radboud University Medical Center, or all of them as a file.
02

Study summary

Work participation is essential for quality of life, providing purpose, social interaction, financial security, and shaping social status. Work participation is increasingly compromised in people with slowly progressive chronic disorders (hereafter referred to as progressive disorders). This negatively impacts their quality of life. Early work-related support, focused on sustainable work-retention, has the potential to enhance work participation in people with progressive disorders. Therefore, this study investigates the (cost)effectiveness of the Preventive Participatory Workplace Intervention (PPWI), a personalized work intervention to enhance sustainable work participation. The investigators perform an 18-month randomized controlled trial (RCT). In addition, the investigators perform a process evaluation and an economic evaluation alongside the RCT. 124 Dutch working persons with three types of movement disorders (Parkinson's Disease (PD), cerebellar ataxia (CA) and hereditary spastic paraparesis (HSP)) and with slowly progressive neuromuscular and mitochondrial disorders will be included.

Read the detailed description

Work participation is essential for quality of life, providing purpose, social interaction, financial security, and shaping social status and personal identity. Work participation is increasingly compromised in people with progressive disorders. This negatively impacts their quality of life. People with slowly progressive chronic disorders (hereafter referred to as progressive disorders) lack (structural) work-related support. Early work-related support, focused on sustainable work-retention, has the potential to enhance work participation in people with progressive disorders. Therefore, the EQuAL-study (Enhancement of Quality of work And Life) investigates the (cost)effectiveness of the Preventive Participatory Workplace Intervention (PPWI), a personalized intervention to enhance sustainable work participation in people with progressive disorders. The aim of the study is to investigate study effects of the PPWI on need for recovery after work (primary endpoint), perceived self-efficacy at work, work-related well-being, quality of life and absenteeism (secondary outcomes). In addition, the PPWI's cost-effectiveness and cost-utility and its the process of implementation and mechanisms of impact will be explored (second and third aim, respectively). To address these aims, the investigators perform an 18 month randomized controlled trial (RCT). A cost and process evaluation will be performed alongside the RCT. 124 Dutch working persons with types of movement disorders will be included: Parkinson's Disease (PD), cerebellar ataxia (CA), and hereditary spastic paraparesis (HSP) and with slowly progressive neuromuscular and mitochondrial disorders. Participants will be recruited from approximately twelve regions across the Netherlands. Participants will be randomised to either the PPWI or an usual care control group in a 1:1 ratio. The PPWI is a process intervention in which a trained process facilitator guides an employee and their manager in identifying work-related obstacles or changes and finding solutions to overcome or manage these obstacles. Its primary goal is to achieve consensus between employee and manager with respect to the most obstructive obstacles for functioning at work and feasible solutions. There are no restrictions on usual care. The study will evaluate between-group differences from baseline to 18-month follow-up in need for recovery after work (primary endpoint) and self-efficacy at work and indicators of quality of life, work-related well-being, and productivity (i.e. absenteeism and presenteeism). For the second aim, the investigators will measure the costs associated with healthcare use, productivity loss, work-related adjustments, and the intervention. For the third aim, the investigators will evaluate the process in terms of implementation of the PPWI, its mechanisms of impact and the implementation context. The investigators envision the PPWI to support sustainable work retention while preserving work-life balance and quality of life for individuals with progressive disorders. Additionally, the trial will provide insights into which intervention components are effective and why. This will help potential future PPWI users in making informed decisions about whether the costs are justified by the anticipated value and benefits.

03

Conditions studied

  • Parkinson Disease
  • Hereditary Spastic Paraparesis
  • Cerebellar Ataxia
  • Mitochondrial Diseases
  • Neuromuscular Diseases (NMD)

Keywords

  • Neurodegenerative disorders
  • Work
  • Quality of life
  • Work-life balance
  • Randomized controlled trial
  • Need for recovery
  • Sustainable work participation
  • Preventive work intervention
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • having a diagnosis Parkinson Disease, cerebellar ataxia, hereditairy spastic paraparesis, or a slowly progressive neuromuscular or mitochondrial disorder, confirmed by the treating physician (e.g. neurologist, rehabilitation physician)
  • aged 18-65 years;
  • being employed for at least 8 hours per week (at baseline). This also includes individuals who have reduced their working hours until reaching this threshold of 8 hours per week. Working time may be distributed across multiple working days;
  • having the intention to continue to work during the study period of 18 months, to prevent inclusion of participants who plan to retire within the 18-month RCT period;
  • being open to talk to the employer or manager about any changes or limitations in work performance (disclosing the diagnosis is not required, by law).

Exclusion criteria

Exclusion Criteria:

  • individuals who are at the beginning of a sick leave procedure (under the Gatekeeper Improvement Act; Wvp);
  • being fully self-employed. Partial self-employment in addition to paid employment is allowed, on the condition that the paid employment accounts for more than half of the total weekly working hours;
  • having a second employer for over eight hours per week;
  • proficiency in the Dutch language is not sufficient;
  • severe comorbidity or health-related event that will hamper compliance to the protocol, e.g. in case of a severe cognitive impairment, a relatively abrupt transition to a very progressive manifestation of the disease, a planned surgery.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Preventive Participatory workplace intervention (PPWI)

    Participants in the PPWI group will receive the PPWI and continue to receive usual care.

    Behavioral: Preventive Participatory workplace intervention

  • No intervention
    Usual care control group

    The usual care control group comprises usual care. There are no restrictions on usual care.

Interventions

  • BehavioralPreventive Participatory workplace intervention

    The Participatory Workplace Intervention (PPWI) is a process intervention in which a trained process facilitator guides an employee and their manager in identifying work-related obstacles or changes and finding solutions to overcome or manage these obstacles. Its primary goal is to achieve consensus between employee and manager with respect to the most obstructive obstacles for functioning at work and feasible solutions. Following consensus, the stakeholders formulate and agree upon a plan of action and execute the plan. In a subsequent meeting, the implementation of the plan of action will be evaluated. Six months after the evaluation, a follow-up will take place to determine whether new obstacles have emerged and whether a new cycle of process steps should be initiated.

06

What researchers measure

Primary outcomes

  1. Need for recovery after work

    Need for recovery after work is measured using the subscale need for recovery after work of the Dutch language version of the Questionnaire on the Experience and Evaluation of Work questionnaire (VBBA 2.0).

    Time frame: Measured four times: at baseline, and after 6, 12 and 18 months

Secondary outcomes

  1. Perceived self-efficacy at work

    Perceived self-efficacy at work is measured with the self-efficacy at work scale. It measures one's perceived self-efficacy in solving work- and disease-related problems and consists of 14 5-point Likert scale items. A higher score indicates a higher level of self-efficacy.

    Time frame: Measured four times: at baseline, and after 6, 12 and 18 months

  2. Work home interference (WHI)

    Work home interference (WHI) is measured with the subscale negative work-home interaction of the Survey Work-home Interaction - NijmeGen (SWING).

    Time frame: Measured four times: at baseline, and after 6, 12 and 18 months

  3. Limitations in work

    Limitations in work is measured with the Dutch language version of the Work Limitations Questionnaire (WLQ-mdlv).

    Time frame: Measured four timepoints: at baseline, and after 6, 12 and 18 months

  4. Work-related stress

    Work-related stress is measured with an 11-point single-item measure. The minimum value is 0 and maximum value is 10. A higher score indicates a higher level of experienced work-related stress.

    Time frame: Measured four times: at baseline, and after 6, 12 and 18 months

  5. Job satisfaction

    Job satisfaction is measured wit an 7-point Likert scale single-item measure. The minimum value is 1 and maximum value is 7. A higher score indicates a higher level of job satisfaction.

    Time frame: Measured four times: at baseline, and after 6, 12 and 18 months

  6. Perceived balance in daily activities (i.e. life balance)

    Percieved balance in daily activities as a parameter life balance, will be measured with the Dutch language version of the Occupational Balance Questionnaire (OBQ11-NL).

    Time frame: Measured four times: at baseline, and after 6, 12 and 18 months

  7. Health-related Quality of Life (QoL)

    Health-related QoL is measured with the EuroQuality of Life Five Dimension (EuroQol 5D (EQ-5D-5L)).

    Time frame: Measured four times: at baseline, and after 6, 12 and 18 months

  8. Overall life satisfaction

    Overall life satisfaction is measured with a single-item life satisfaction measure with an 11- point answer scale. The minimum value is 0 and maximum value is 10. A higher score indicates a higher level of life satisfaction.

    Time frame: Measured four times: at baseline, and after 6, 12 and 18 months

  9. Absenteeism

    Absenteeism data include dates of sick and recovery notifications, working hours of absence, and whether the sick notification was related to the movement disorder. At the baseline measurement, absenteeism data will be collected through a questionnaire applying a recall period of three months. Upon participation, we ask participants to keep track of their absenteeism on a scheme we provide them with.

    Time frame: Measured four times: at baseline, and after 6, 12 and 18 months

  10. Presenteeism

    Presenteeism refers to when employees show up to work despite being ill, that leads to reduced productivity. Presenteeism is measured with the presenteeism subscale of the iMTA Productivity Cost Questionnaire (iPCQ).

    Time frame: Measured four times: at baseline, and after 6, 12 and 18 months

Other outcomes

  1. Healthcare and occupational service utilization

    Primary and secondary healthcare and occupational service utilization (e.g. appointment with a rehabilitation physician, a physiotherapist or an occupational physician) will be measured through questionnaires. Participants will be asked to keep track of their healthcare and occupational service utilization over the past six months prior to each measurement. For this purpose, we provide participants with a scheme. Healthcare costs will be obtained by multiplying the utilization quantities with the costs per quantity, based on the cost calculation guidelines established for healthcare in the Netherlands in 2024. Occupational service utilization costs are calculated using tariffs for occupational service professionals.

    Time frame: Measured four three times: at 6, 12 and 18 months

  2. Productivity (loss) costs (due to absenteeism)

    Absenteeism data that are collected for the purpose of the effect evaluation, will be included as a third component. For the absenteeism costs, different calculation approaches will be used for the societal and employer's perspective (for the purpose of the economic evaluation). The societal perspective applies the iPCQ calculation guidelines, using the friction cost method. This method is based on the assumption that employees on long-term sick leave are eventually replaced. As a result, productivity losses primarily occur during the period required for an employer to replace an absent employee, known as the friction period. For the employer's perspective, absenteeism costs will be estimated using the Human Capital Approach (HCA).

    Time frame: Measured four times: at baseline, and after 6, 12 and 18 months

  3. Productivity (loss) costs (due to presenteeism and loss unpaid work)

    Productivity loss due to presenteeism and loss unpaid work will be measured and valued using two iMTA Productivity Cost Questionnaire (iPCQ) modules \[50\], measuring productivity losses of paid work due to presenteeism and losses related to unpaid work. Costs will be calculated according to the iPCQ calculation guidelines and a standard production costs per hour.

    Time frame: Measured four times: at baseline, and after 6, 12 and 18 months

  4. Costs for work-related adjustments

    At T3, participants will be asked whether any work-related adjustments have been implemented during the study period and, if so, which adjustments were made. Participants are asked to fill in workplace adjustments, such as an adapted desk chair, and 'other' types of work-related adjustments. To estimate the associated costs, average acquisition costs for each adjustment will be applied.

    Time frame: Measured one timepoint: at 18 months

  5. Intervention costs

    Data on time spent on the PPWI trajectory by process facilitators will be collected continuously through checklists. Process facilitators will report the actual (direct) time and indirect participant-related time spent per meeting, and, if applicable, the travel time. The intervention costs will be calculated by multiplying the hours registered by the process facilitators with the tariffs for occupational therapy in the Netherlands.

    Time frame: After every intervention-session with a participant, from the date on which the first participant starts with the intervention until 18 months after the date of inclusion of the last participant.

  6. Recruitment (process evaluation outcome)

    Recruitment strategies that are used to reach and recruit participants. The recruitment strategies are registered by the investigator.

    Time frame: Pre-intervention (2 weeks before start recruitment),during recruitment period (monthly registration), 2 weeks after end recruitment period.

  7. Reach (process evaluation outcome)

    Proportion of the target audience that participates in the intervention. Reach is determined, based on: the number of individuals invited to participate in the trial, number of individuals potentially interested and the number of participants who participated (in the intervention group). Data on these variables are registered by the intervention providers.

    Time frame: Weekly registration, from the date of randomization of the first participant until the date of randomization of the last participant, assessed up to 18 months.

  8. Dose delivered (process evaluation outcome)

    Dose delivered is determined by the amount of meetings planned and intervention steps provided according to the protocol by the intervention providers. Dose delivered is determined, based on: the number of meetings that have taken place and the number of process steps that have been performed. Data on these variables will be retrieved from the intervention providers, by questionnaires.

    Time frame: After every intervention-session with a participant, from the date on which the first participant starts with the intervention until 18 months after the date of inclusion of the last participant.

  9. Dose received (process evaluation outcome)

    Dose received is the extent to which participants actively engage with the intervention. Dose received is determined, based on: the extent to which all stakeholders involved have implemented the solutions as proposed during the participatory workplace intervention. Data on this outcome is retrieved by both participants and intervention providers, by questionnaires.

    Time frame: Post-intervention (at 18 months after baseline)

  10. Fidelity (process evaluation outcome)

    Fidelity is the extent to which the intervention steps are delivered according to the protocol. Fidelity is determined, based on: whether the predefined fidelity criteria have been reached. Data on fidelity is retrieved from the intervention providers, by a questionnaire.

    Time frame: After every intervention-session with a participant, from the date on which the first participant starts with the intervention until 18 months after the date of inclusion of the last participant.

  11. Satisfaction with the intervention (process evaluation outcome)

    Satisfaction with the intervention in general, intervention steps, materials of the intervention, the intervention provider and the solutions that came out of the intervention. Data on satisfaction with the intervention will be retrieved from participants, by a questionnaire.

    Time frame: Post-intervention (at 18 months after baseline)

  12. Perceived impact (process evaluation outcome)

    Perceived impact/effect is determined, based on: whether and how participants experienced that the intervention improved working and/or living conditions and functioning and which components of the intervention contributed to that (or not) Data on perceived impact of the intervention will be retrieved from (a subset of) participants, through semi-structured in-depth interviews.

    Time frame: Post-intervention (in period of 18-20 months after baseline)

  13. Perceived benefit for participants (process evaluation outcome)

    Perceived benefit for participants is determined, based on: whether and how intervention providers perceived that the intervention improved working and/or living conditions and functioning of participants and which components of the intervention contributed to that (or not). Data on perceived benefit will be retrieved from the intervention providers, through focus-group interviews.

    Time frame: 1 year after inclusion of last participants

  14. Facilitators and barriers (process evaluation outcome)

    Factors that either facilitate or hamper functioning and implementation of the intervention. Data will be retrieved from both intervention providers through focus-group interviews and from (a subset of) participants, through semi-structured in-depth interviews.

    Time frame: Post-intervention (in period of 18-20 months after baseline)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Relevant and anonymised research data will be shared/published in the Radboud Data Repository (RDR) to guarantee long-term accessibility to the research data of the project of this research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: After completion of the measurements and analysis, relevant and anonymised research data will be placed on the RDR.

Access criteria: The pseudonymized research data will be accessible in the RDR under restricted access. This means that researchers who are interested in re-use of the data are asked to contact the central contact person for permission. Approval is given after a signed agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Mar 2027, 28 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 28 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2024
First posted
Aug 27, 2024
StartActual
Oct 8, 2024
Primary completionEst.
Mar 4, 2027
CompletionEst.
Mar 4, 2027
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06573866
Responsible party
Sponsor
First posted
Aug 27, 2024
Start date
Oct 8, 2024
Primary completion
Mar 4, 2027 (estimated)
Completion
Mar 4, 2027 (estimated)
Last update
Aug 14, 2026

Study contacts

Elbrich Postma, PhD
principal investigator · Radboud University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion